IDEAYA Biosciences, Inc. — Form 10-Q
Filed August 4, 2026 · analyzed by the Periodic Agent
10-Q
— Neutral
significance 18/100
What the filing says
IDEAYA amended its Non-Employee Director Compensation Program effective June 16, 2026. Cash retainers range from $45,000 annually for base non-employee directors to $35,000 for non-executive chair, plus committee chair/member supplements. Equity grants include 40,000-share options for new directors vesting monthly over 3 years, and 20,000-share annual options vesting within 1 year, with full acceleration on change of control.
Why this rating
Routine governance disclosure; director comp <0.1% of $1.8B market cap; standard practice alignment with peer biotech firms.
See more from August 4, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.